feed,title,long_url,short_url
Benzinga,FDA's Office Agrees On 12-Month Reduction In Pain As Primary Endpoint For Mesoblast's Back Pain Study,https://benzinga.com/general/biotech/21/12/24643027/fdas-office-agrees-on-12-month-reduction-in-pain-as-primary-endpoint-for-mesoblasts-back-pain-stu,https://j.mp/3q2foOr
Benzinga,Trinity Biotech Enters Into $81M Loan Facility To Refinance Existing Debt,https://benzinga.com/news/earnings/21/12/24642089/trinity-biotech-enters-into-81m-loan-facility-to-refinance-existing-debt,https://j.mp/3oXH1cc
